1TapiSiz OL,Gungor T,Aytan H,et 81. Does hysterectomy affect o- varian function? Histopathologic evaluation and serum FSH, in- hibin A,and inhibin B levels in an experimental rat model. Eur J Obstet Gynecol Reprod Biol,2008 , 140 ( 1 ) :61.
2Stramba - Badiale M. Postmenopausal hormone therapy and the risk of cardiovascular disease. J Cardiovasc Med (Hagerstown) , 2009,10(4) :303.
3Ito K. Hormone replacement therapy and cancers: the biological roles of estrogen and progestin in tumorigenesis are different be- tween the endometrium and breast. Tohoku J Exp Med,2007,212 (t):t.
6Rossouv JE, Prentice RE, Manson JE, et al. Postmenopausal hormone therapy and risk of cardiovascular disease by age and years since menopause. JAMA,2007.297(13):1465-1477.
7Collins P Rosano G, Casey C, et al. Management of cardiovascular risk in the peri-menopausal women: a consensus statement of European cardiologists and gynaecologists. Eur Heart J,2007.28(16) :2028-2040.
8Ichikawa J, Sumino H, Ichikawa S, et al. Different effects of transdermal and oral hormone replacement therapy on the renin-angiotensin system, plasma bradykinin level, and blood pressure of normotensive postmenopausal women. Am J Hypertens,2006 , 19(7) :744-749.
9Odmark IS, Carlstrom K, Jonsson B, et al. Conjugated estrogen/progestagen versus tibolone hormone replacement therapy in postmenopausal women: effects on carbohydrate metabolism and serum sex hormone-binding globulin. Maturitas,2006,53(1) :89-96.
10The Writing Group for the PEPI trial. Effects of estrogen or estrogen/progestin regimens on heart disease risk factors in postmenopausal women, the postmenopausal estrogen/ progestin interventions (PEPI) trial. JAMA, 1995, 273 (3) : 199-208.
